Nutriband Inc. (NTRB) investor relations documents from the company's IR site: 2 presentations, 7 press releases; latest deck 2024-08-22. Read in-app with summaries. First-party data.
Full Profile — Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company developing AVERSA, an abuse-deterrent transdermal patch technology, with peak sales of $200M expected.
| Published | Type | Document |
|---|---|---|
| 2025-09-12 | Press release | nutriband publishes q2 report and announces key fda meeting for aversa fentanyl |
| 2024-12-04 | Press release | nutriband inc announces financial results for the third quarter of 2024 |
| 2024-10-02 | Press release | join nutriband s exclusive live investor webinar and q a session on october 17 |
| 2024-08-22 | Presentation | Full Profile |
| 2024-06-03 | Press release | nutriband inc quarterly report emphasizes focus on kinesiology tape output as q1 sports tape revenu |
| 2023-07-05 | Presentation | View our latest investor presentation here |
| 2023-04-27 | Press release | nutriband inc reports revenue up 46 in fiscal 2023 |
| 2022-04-29 | Press release | nutriband inc reports revenue up 56 in fiscal 2022 to a record 1 4m |
| 2020-12-16 | Press release | nutriband inc records record 375 year over year increase in third quarter revenues and record 69 |
NTRB overview · NTRB earnings · NTRB financials · NTRB KPIs · NTRB ownership · NTRB peers · NTRB filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.